NovaSOL® Curcumin – bioavailability proven in major research project
Aquanova participated in a major (independent) study (“Novel strategies for the enhancement of the potency of nutraceuticals with low oral bioavailability and their application in novel functional foods for optimum protection of the aging brain”) within the research network sponsored by the German Federal Ministry of Education and Research.
The project, led by Prof. Dr. Jan Frank, was conducted with participation of four renowned universities (Hohenheim, Frankfurt, Jena, Kiel,).
As part of this research, NovaSOL® was examined with respect to its enhancement of bioavailability within a state of the art human clinical trial:
- Oral dose of 500mg Curcumin
- Materials used:
- Native curcumin extract
- Curcumin micronisate
- NovaSOL® Curcumin
- 23 participants: 13 women / 10 men
The results for NovaSOL® within this human clinical are overwhelming (the figures relate the NovaSOL® values to the native curcumin extract):
- Bioavailability factor curcumin AUC, 24h: 185
- Bioavailability factor curcumin Cmax: 453
- Tmax factor curcumin: 6.8 (1.1h vs. 7.5h native)
The study results have been published in January 2014 in Molecular Nutrition & Food Research (Volume 58, Issue 3, pages 516-527). Research NovaSOL® Curcumin rated #1 by Wiley.
